MedPath

Food Intake and IgA Microbiota in Anorexia Nervosa

Not Applicable
Recruiting
Conditions
Anorexia Nervosa
Healthy Volunteer
Registration Number
NCT05842343
Lead Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Brief Summary

Anorexia nervosa is characterized by intestinal dysbiosis, related to the feeding behavior impairment presented by these patients. Pathophysiologic hypotheses are involving the trouble of the microbiota-gut-brain axis in the field of mental diseases.

Detailed Description

Anorexia nervosa is characterized by intestinal dysbiosis, related to the feeding behavior impairment presented by these patients. Here we aim to characterize the IgA-coated fraction of bacteria from the intestinal microbiota, linked to the regulation of the mucosal immune system and the epithelium physiology. Abnormalities of this microbiota are reported in inflammatory bowel disease and are associated to immune trouble. As food intake plays a key role in shaping microbiota, we aim to correlate data from IgA microbiota to food intake specificity, and to anorexia nervosa phenotypes.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
80
Inclusion Criteria
  • female subject, adult, affiliated to a social security system, under the care of the eating disorder department of university hospital of st Etienne
  • presenting a diagnosis of pure restrictive anorexia nervosa.

For acute subgroup : BMI between 11 and 17.5 kg/m2, patient with a first episode of restrictive anorexia nervosa or with hyperphagic episodes.

For the chronic subgroup: BMI between 11 and 17.5 kg/m2, disease evolving for more than 5 years.

For Healthy volunteer: BMI between 20 and 24 kg/m², stable weight for the last 3 months, no eating disorder or history of eating disorder

Exclusion Criteria
  • patient does not understand French.
  • laxative treatment in progress or stopped for less than 15 days,
  • antibiotic treatment in the two months preceding inclusion,
  • pre-pro or symbiotic treatment in progress or in the month preceding inclusion,
  • patient with one of the following comorbid disorders: celiac disease, chronic inflammatory bowel disease, lactose intolerance, unstabilized hyperthyroidism, unstabilized diabetes,
  • subject under legal protective measures.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Total microbiotic profile1 week after inclusion

abundance and diversity parameters of the IgA microbiota fraction of the intestinal microbiota obtained by 16s rDNA analysis of stool suspension samples from acute anorexia nervosa, chronic anorexia nervosa and control subjects.

Secondary Outcome Measures
NameTimeMethod
Food intake characteristics1 week after inclusion

Qualitative and quantitative assessment of dietary intake by a dietary survey of acute anorexia nervosa, chronic anorexia nervosa and control subjects.

ELISA assay of fecal immunoglobulins1 week after inclusion

ELISA determination of immunoglobulin A and immunoglobulin M in the stool of acute anorexia nervosa, chronic anorexia nervosa and control subjects.

Microbiotic profile of total intestinal microbiota1 week after inclusion

Total microbiotic profile (abundance and diversity) of the intestinal microbiota obtained by 16s rDNA analysis of stool suspension samples from acute anorexia nervosa, chronic anorexia nervosa and control subjects.

Trial Locations

Locations (1)

Chu Saint-Etienne

🇫🇷

Saint-Étienne, France

Chu Saint-Etienne
🇫🇷Saint-Étienne, France
Tristan GABRIEL-SEGARD, Md
Contact
04 77 12 02 61
Tristan.Gabriel-Segard@chu-st-etienne.fr
Bogdan GALUSCA, Md
Sub Investigator
Natacha GERMAIN, Md
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.